The global generics market totaled $83 billion in 2009. Generic drugs account for more than 70% of prescriptions dispensed in the U.S. Continued growth is expected as brand drugs face increased generic competition. By 2014, branded prescription sales of $89 billion will be at risk for generic competition.
This report focusing on the Top 50 Specialty Companies features a compilation of generic, drug-delivery, drug-development, niche pharmaceutical, and other specialty healthcare players.
The report ranks the top 50 specialty companies that are publicly traded by 2009 revenue. The charts for the specialty companies encompass total revenue, R&D expenditure, net income, earnings per share, total assets, and shareholders' equity for 2009 and 2008, as well as headquarters location, Website and the main areas of business concentration.
Profiles on each company include a business overview, select 2010 news, quick facts and key products, and most-recent quarterly financial results.
Additionally provided are chart breakdowns of revenue and the number of companies for the specialty pharmaceutical, generic, and drug-delivery sectors.